… ProQR Announces Year End 2023 Operating and Financial Results … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We announced our initial pipeline programs, AX-0810 …
… ProQR Announces First Quarter 2025 Operating and Financial … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … $1.0 million (€ 918,000). Research and development (R&D) costs were € 12.3 million for the quarter ended March …
… ProQR Announces First Quarter 2023 Operating and Financial … & CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company … 31, 2023, and provided a business update. “During our R&D event in Q1, we provided a comprehensive update on how …
… ProQR Announces Results for the Second Quarter of 2017 Key … in need,“ said Daniel de Boer, Chief Executive Officer of ProQR. “We have made significant progress in all of our … the Axiomer ® platform technology we announced at our R&D day. I’m proud of our scientific team to have invented …
… ProQR Announces Third Quarter 2022 Operating and Financial … to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023 Management Team appointments … & CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… ProQR Announces Third Quarter 2023 Operating and Financial … NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We expect that the body of data on our platform and …
… ProQR Announces Second Quarter 2023 Operating and Financial … of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Second Quarter 2025 Operating and Financial … & CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company … $2.0 million (~€ 1.8 million). Research and development (R&D) costs were € 23.7 million for the six month period ended …
… ProQR Announces First Quarter 2022 Operating and Financial … & CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … for the same period last year. Research and development (R&D) costs were €13.4 million for the quarter ended March 31, …